Detalles de la búsqueda
1.
Cefepime-Taniborbactam in Complicated Urinary Tract Infection.
N Engl J Med
; 390(7): 611-622, 2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38354140
2.
Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection.
Antimicrob Agents Chemother
; : e0023624, 2024 May 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38780262
3.
Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States.
Antimicrob Agents Chemother
; 67(11): e0049823, 2023 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37768313
4.
In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program.
Antimicrob Agents Chemother
; 67(1): e0128122, 2023 01 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36541767
5.
Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-ß-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018-2020 Global Surveillance Collection.
Antimicrob Agents Chemother
; 66(11): e0093422, 2022 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36286518
6.
Cefepime-Taniborbactam in Complicated Urinary Tract Infection. Reply.
N Engl J Med
; 390(20): 1938-1939, 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38810202
7.
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-ß-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa.
Antimicrob Agents Chemother
; 64(3)2020 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31871094
8.
Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
Antimicrob Agents Chemother
; 62(1)2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29109163
9.
Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies.
Antimicrob Agents Chemother
; 62(4)2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29358292
10.
Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Infection.
Antimicrob Agents Chemother
; 61(10)2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28784674
11.
Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
Antimicrob Agents Chemother
; 61(2)2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27956417
12.
Single-dose oritavancin in the treatment of acute bacterial skin infections.
N Engl J Med
; 370(23): 2180-90, 2014 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-24897083
13.
Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State.
Antimicrob Agents Chemother
; 60(7): 4342-5, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27067327
14.
Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.
Antimicrob Agents Chemother
; 60(5): 3174-7, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26926647
15.
Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.
Clin Infect Dis
; 60(2): 254-62, 2015 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25294250
16.
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Antimicrob Agents Chemother
; 59(4): 2405-9, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25666152
17.
Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
Antimicrob Agents Chemother
; 57(1): 205-11, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23089749
18.
Dalbavancin or oritavancin for skin infections.
N Engl J Med
; 371(12): 1162-3, 2014 09 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-25243251
19.
Comparative in vitro activity of oritavancin and other agents against vancomycin-susceptible and -resistant enterococci.
J Antimicrob Chemother
; 72(2): 622-624, 2017 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-27856721
20.
Genome annotation and intraviral interactome for the Streptococcus pneumoniae virulent phage Dp-1.
J Bacteriol
; 193(2): 551-62, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21097633